The problem of liver related diseases is increasing due to irregular eating and random lifestyle. Fatty liver is a major problem in liver problems, which can cause various serious diseases and health complications including diabetes, cardiovascular diseases and high blood pressure. "By controlling the amount of fat or fat of the liver, keeping it below five percent, then these serious diseases and health complications can be avoided."

Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ® (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight. This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.



































